Lifecare ASA · OSL:LIFE
Lifecare ASA — Redeye Lifecare presentation (September 2023)
29 slides from Lifecare ASA's conference presentation, Sep 26, 2023
Slide 1: Company presentation September 2023
Company presentation September 2023
Slide 2: Disclaimer
Disclaimer The information in this presentation has been prepared by Lifecare (the “Company”). This presentation does not constitute a recommendation regarding any securities of the Company. By accepting to attend this presentation and/or receive this information, you agree to be bound by the follow
Slide 3: Clinical stage sensor company developing the world's smallest Continuous Glucose Monitor
Clinical stage sensor company developing the worlds smallest Continuous Glucose Monitor 26.09.23 3
Slide 4: Trigger Events
Trigger Events Q3 2023 Q4 2023 Q1 2024 Q2 2024 Place order - Automated Production and Automation Automated pilot production software for automated market launch production production equipment production - Product launch for veterinary market - Start LFC-SEN- - Conclude Approval for Studies 002 LFC-
Slide 5: Product development agreement with Sanofi
Product development agreement with Sanofi Sanofi-Avenis Group sponsor the development program for miniaturizing the Sencell Glucose sensor with funding of EUR 290.000 based on completion of defined development phases The Development Agreement is based on a robust evaluation and due diligence process
Slide 6: Diabetes prevalence
Diabetes prevalence Million people (all ages) living with diabetes, worldwide 2 1400 1 in 10 1200 1000 adults1 worldwide live with diabetes 800 2021 (2021 : 4852 - 537 3million people) 600 2050 400 Projected to reach 1,3 billion people in 2050 2 200 0 1 Age 20 -79, 2 Lancet June 2023, 3 IDF Diabetes
Slide 7: Patient Glucose Monitoring
Patient Glucose Monitoring Standard treatment Blood Glucose Meter State-of-the art treatment Continuos Glucose Monitor 26.09.23 7
Slide 8: Sensing principles – Continuous Glucose Monitoring
Sensing principles – Continuous Glucose Monitoring 1 Glucose oxidase 2 Flourescence 3 Osmotic pressure Dexcom (G6 & G7), Medtronic, Abbott Senseonics (Eversense) Lifecare (Sencell) (FreeStyle Libre 2 & 3) Longevity: 7- 14 days Longevity: 180 days Longevity: 172 days (in-vitro) Annual cost: $ 1.500 –
Slide 9: Sencell system
Sencell system ü Size of a grain of rice ü Injected under the skin ü 6 months longevity ü No calibration needed 26.09.23 9
Slide 10: 1 Sensing principle
Unique technology 1 Sensing principle 26.09.23 10
Slide 11: Sensing principle – Osmotic pressure
Sensing principle – Osmotic pressure Movement of liquid from less concentrated to the more concentrated solution through a semi-permeable membrane. 26.09.23 11
Slide 12: 2 Nanoscale sensor
Unique technology 2 Nanoscale sensor 26.09.23 12
Slide 13: Nanoscale sensing elements
Nanoscale sensing elements 26.09.23 13
Slide 14: 3 Chemistry
Unique technology 3 Chemistry 26.09.23 14
Slide 15: Patented chemistry solution
Patented chemistry solution Lifecares patented chemistry solution consists of ConA and Dextrane, forming a dynamic system reactive to glucose - causing increase or decrease of osmotic pressure. New chemistry under development: modular system for customization to various molecules beyond glucose. New
Slide 16: Clinical status
Study «LFC-SEN-001» – concluded May 2023 Clinical status presented at American Diabetes Association Scientific Sessions June 23 Purpose: Collect human proof-of-concept performance data for algorithm development during meal experiments and for further device optimization Conclusion: Subcutaneous gluc
Slide 17: Clinical accuracy – Consensus error grid
Clinical accuracy – Consensus error grid (ISO 15197: BG meters) Results in zone A and B: LFC-SEN-001: Retrospective regulatory accepted consensus error-grid analysis 26.09.23 17
Slide 18: Market Continuous Glucose Monitoring
Market Continuous Glucose Monitoring 540 million people living with diabetes 2,88 million dogs and cats living 90 million people need with diabetes glucose monitoring (Europe and US) Q1 2023 Global CGM Veterinary glucometer userbase 7 million1 market size is projected to be valued at US$ 251,3 Globa
Slide 19: Potential target patient population
Potential target patient population Regions Population Primary Primary Total target targeted by with Target Target Type population Lifecare diabetes Type 1 2 (T2DM) (T1DM) EU, EEA, UK, 36 Mill 2,3 Mill 6,3 Mill 8,6 Mill CH US, CA 51 Mill 2,7 Mill 7,2 Mill 9,9 Mill High Income 29 Mill 2,1 Mill 5,6 Mi
Slide 20: Potential veterinary target population
Potential veterinary target population 1200000 1000000 800000 600000 400000 200000 0 Nordic Europe US Diabetes dogs Diabetes cats 26.09.23 20
Slide 21: Sencell Human Market Potential
Sencell Human Market Potential The basis for the market potential is described in the document “SENCELL Market Assumptions and Commercial Potential, April 2022» available for downloading at www.lifecare.no Assuming lower cost and longevity, accurate and user-friendly measurements - indicates potenti
Slide 22: Sencell – Potential Revenue Calculation (Human market)
Sencell – Potential Revenue Calculation (Human market) Market penetration Sencell Base Case Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Level of assumed market penetration - base case EU, UK, EEA and CH 5% 20 % 40 % 80 % 95 % 100 % 100 % US and CA 0% 0% 10 % 30 % 50 % 75 % 95 % AU, CL, IL, JP,
Slide 23: Lifecare group structure
Lifecare AS Bergen, Norway Group HQ Listed on Euronext Growth Oslo Lifecare Laboratory GmbH Lifecare NanoBioSenosors GmbH Lifecare Chemistry Ltd Lifecare Veterinary AS Mainz, DE Reutlingen, DE Bath, UK Bergen, Norway ISO 9001 Certified Sensor development and manufacturing Development of sensor chemi
Slide 24: Directors and officers
Directors and officers Board of Directors Chief Executive Officer Chief Scientific Officer Morten Foros Joacim Prof. Dr. Dr. Krohnstad Holter Med. Andreas Pfützner Chairman of the Board Kronstad is a partner in the LL.M. from University of MD and teaching professor law-firm Schjødt and an Bergen exp
Slide 25: Scientific Advisors and Consultants
Scientific Advisors and Consultants Prof. David Klonoff Prof. Lutz Heinemann Prof. Kristin P. Prof. Kåre Birkeland Prof. Michael Huth Prof. Tony James Chairman Scientific Board of Directors and Anfinsen, Scientific Advisory Scientific Advisory Scientific Consultant, Advisory Board, Scientific Adviso
Slide 26: Mainz: manufacturing facilities for volume production
Mainz: manufacturing facilities for volume production 26.09.23 26
Slide 27: Investment history
Investment history Total investment 2006 - 2022 83% Equity - 17% Public funding 165 MNOK Public listing/Capital increase 2018 Equity 33MNOK Capital increase 2021 Equity 26MNOK Capital increase 2022 Equity 45MNOK 26.09.23 27
Slide 28: Committed shareholders
Committed shareholders 26.09.23 28
Slide 29: © LIFECARE
© LIFECARE
Lifecare — Redeye Lifecare presentation (September 2023) on 6ix